Comphya SA, a pioneering medical technology company and the developer of CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction announced recently the successful closure of the first tranche of its Series A1 funding round. This achievement strengthens Comphya’s financial position, enabling the continued advancement and expansion of its groundbreaking clinical trials.
The total funding of CHF 4.35 million includes a combination of converted Convertible Loan and newly raised equity capital. The proceeds from this funding round will be instrumental in advancing our clinical trials across Australia, Brazil, and the United States, which have already demonstrated promising results.
“This new funding positions Comphya to accelerate the delivery of our groundbreaking solution to restore erectile function, while driving significant value for patients and stakeholders,” said Dr. Rodrigo Fraga, CEO of Comphya. “We deeply appreciate the trust and confidence our investors have placed in our vision and mission.”
Dr. Steve Swinson, Chairman of the Board, added, “This achievement is a testament to the unwavering dedication of our team, the trust of our investors, and the invaluable support of our key opinion leaders, including Prof. Arthur Burnett, Prof. Anthony Costello, Prof. Sidney Glina, and Dr. Phil Dundee. We extend our heartfelt gratitude to everyone who has contributed to Comphya’s success.”
Treating erectile dysfunction caused by mechanical nerve damage
CaverSTIM is the first implantable neurostimulator designed to restore erectile function. This innovative technology is primarily intended for patients who are non-responders to oral medications, such as post-prostatectomy patients. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal. It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection.
(PR)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines